Abstract: Both Sp2CBMTD and Vc2CBMTD were shown to reduce the apical viral load of RSV-infected human airway epithelial cells. The degree of reduction was dependent on the type of mCBM and number of doses administered. Exposure of infected MucilAlr inserts to Sp2CBMTD did not show a significant effect on viral replication due to variability of data but a slight reduction was observed at the highest dose (100 ?g) after two doses at 48 h p.i (see FIG. 23A), and after three doses at 96 h p.i. compared to virus infected control. Exposure to Vc2CBMTD (100 ?g) was more effective in reducing RSV viral replication in both dosing regimens than using a 10 ?g dosing regimen. Although not statistically significant, the reduction of viral load at 48 h p.i was observed to decreased greater than 1 log (FIG. 23B).

Abstract: The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial vims (RSV).

Abstract: Disclosed are molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), for use in treating or preventing of inflammatory diseases and/or conditions with an inflammatory aeitiology. The disclosed molecules may be of particular use in the treatment and/or prevention of diseases and/or conditions characterised by inflammation occurring as a consequence of a cascade of cytokines, inflammation that may occur in and around the tissues and/or structures of the lung and inflammation occurring as a result of an infection.

Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.

Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.

Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.

Abstract: The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial virus (RSV).